Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#41
REVIEW
Simon Feys, Agostinho Carvalho, Cornelius J Clancy, Jean-Pierre Gangneux, Martin Hoenigl, Katrien Lagrou, Bart J A Rijnders, Laura Seldeslachts, Lore Vanderbeke, Frank L van de Veerdonk, Paul E Verweij, Joost Wauters
Influenza-associated pulmonary aspergillosis (IAPA) and COVID-19-associated pulmonary aspergillosis (CAPA) are increasingly recognised as important complications in patients requiring intensive care for severe viral pneumonia. The diagnosis can typically be made in 10-20% of patients with severe influenza or COVID-19, but only when appropriate diagnostic tools are used. Bronchoalveolar lavage sampling for culture, galactomannan testing, and PCR forms the cornerstone of diagnosis, whereas visual examination of the tracheobronchial tract during bronchoscopy is required to detect invasive Aspergillus tracheobronchitis...
July 15, 2024: Lancet Respiratory Medicine
#42
JOURNAL ARTICLE
Tony Kirby
No abstract text is available yet for this article.
July 12, 2024: Lancet Respiratory Medicine
#43
JOURNAL ARTICLE
Evangelos J Giamarellos-Bourboulis
No abstract text is available yet for this article.
July 11, 2024: Lancet Respiratory Medicine
#44
JOURNAL ARTICLE
Paul Little, Jane Vennik, Kate Rumsby, Beth Stuart, Taeko Becque, Michael Moore, Nick Francis, Alastair D Hay, Theo Verheij, Katherine Bradbury, Kate Greenwell, Laura Dennison, Sian Holt, James Denison-Day, Ben Ainsworth, James Raftery, Tammy Thomas, Christopher C Butler, Samantha Richards-Hall, Deb Smith, Hazel Patel, Samantha Williams, Jane Barnett, Karen Middleton, Sascha Miller, Sophie Johnson, Jacqui Nuttall, Fran Webley, Tracey Sach, Lucy Yardley, Adam W A Geraghty
BACKGROUND: A small amount of evidence suggests that nasal sprays, or physical activity and stress management, could shorten the duration of respiratory infections. This study aimed to assess the effect of nasal sprays or a behavioural intervention promoting physical activity and stress management on respiratory illnesses, compared with usual care. METHODS: This randomised, controlled, open-label, parallel-group trial was done at 332 general practitioner practices in the UK...
July 11, 2024: Lancet Respiratory Medicine
#45
JOURNAL ARTICLE
Talha Burki
No abstract text is available yet for this article.
July 9, 2024: Lancet Respiratory Medicine
#46
JOURNAL ARTICLE
Peter Ranscombe
No abstract text is available yet for this article.
July 8, 2024: Lancet Respiratory Medicine
#47
REVIEW
Sjanna B Besteman, Debby Bogaert, Louis Bont, Asuncion Mejias, Octavio Ramilo, Daniel M Weinberger, Ron Dagan
Lower respiratory tract infections, commonly caused by respiratory syncytial virus (RSV) or Streptococcus pneumoniae (pneumococcus), pose a substantial global health burden, especially in children younger than 5 years of age. A deeper understanding of the relationship between RSV and pneumococcus would aid the development of health-care approaches to disease prevention and management. We completed a systematic review to identify and assess evidence pertaining to the relationship between RSV and pneumococcus in the pathogenesis of childhood respiratory infections...
July 8, 2024: Lancet Respiratory Medicine
#48
REVIEW
Merete B Long, Sanjay H Chotirmall, Michal Shteinberg, James D Chalmers
Bronchiectasis is understood to be the result of a complex interaction between infection, impaired mucociliary clearance, inflammation, and lung damage. Current therapeutic approaches to bronchiectasis are heavily focused on management of infection along with enhancing mucus clearance. Long-term antibiotics have had limited success in clinical trials, suggesting a need to re-evaluate the concept of bronchiectasis as an infective disorder. We invoke the example of asthma, for which treatment paradigms shifted away from targeting smooth muscle constriction, towards permanently suppressing airway inflammation, reducing risk and ultimately inducing remission with precision anti-inflammatory treatments...
July 3, 2024: Lancet Respiratory Medicine
#49
JOURNAL ARTICLE
Priya Venkatesan
No abstract text is available yet for this article.
June 20, 2024: Lancet Respiratory Medicine
#50
LETTER
Eric Lim, Chris Rogers
No abstract text is available yet for this article.
September 2024: Lancet Respiratory Medicine
#51
LETTER
Marcello Migliore
No abstract text is available yet for this article.
September 2024: Lancet Respiratory Medicine
#52
LETTER
Yumna Ahmed, Agha Muhammad Hammad Khan, Calogero Casa, Ahmed Nadeem Abbasi
No abstract text is available yet for this article.
September 2024: Lancet Respiratory Medicine
#53
LETTER
Peter Zhan, Daniel J Boffa, Gavitt A Woodard
No abstract text is available yet for this article.
September 2024: Lancet Respiratory Medicine
#54
JOURNAL ARTICLE
Margaux M I Meslé, Jeremy Brown, Piers Mook, Mark A Katz, José Hagan, Roberta Pastore, Bernhard Benka, Monika Redlberger-Fritz, Nathalie Bossuyt, Veerle Stouten, Catharina Vernemmen, Elisabet Constantinou, Marek Maly, Jan Kynčl, Ondrej Sanca, Tyra Grove Krause, Lasse Skafte Vestergaard, Tuija Leino, Eero Poukka, Kassiani Gkolfinopoulou, Kassiani Mellou, Maria Tsintziloni, Zsuzsanna Molnár, Gudrun Aspelund, Marianna Thordardottir, Lisa Domegan, Eva Kelly, Joan O'Donell, Alberto-Mateo Urdiales, Flavia Riccardo, Chiara Sacco, Viktoras Bumšteinas, Rasa Liausediene, Joël Mossong, Anne Vergison, Maria-Louise Borg, Tanya Melillo, Dragan Kocinski, Enkela Pollozhani, Hinta Meijerink, Diana Costa, João Paulo Gomes, Pedro Pinto Leite, Alina Druc, Veaceslav Gutu, Valentin Mita, Mihaela Lazar, Rodica Popescu, Odette Popovici, Monika Musilová, Maja Mrzel, Maja Socan, Veronika Učakar, Aurora Limia, Clara Mazagatos, Carmen Olmedo, Gavin Dabrera, Meaghan Kall, Mary Sinnathamby, Graham McGowan, Jim McMenamin, Kirsty Morrison, Dorit Nitzan, Marc-Alain Widdowson, Catherine Smallwood, Richard Pebody
BACKGROUND: By March, 2023, 54 countries, areas, and territories (hereafter CAT) in the WHO European Region had reported more than 2·2 million COVID-19-related deaths to the WHO Regional Office for Europe. Here, we estimated how many lives were directly saved by vaccinating adults in the WHO European Region from December, 2020, to March, 2023. METHODS: In this retrospective surveillance study, we estimated the number of lives directly saved by age group, vaccine dose, and circulating variant-of-concern (VOC) period, regionally and nationally, using weekly data on COVID-19 mortality and infection, COVID-19 vaccination uptake, and SARS-CoV-2 virus characterisations by lineage downloaded from The European Surveillance System on June 11, 2023, as well as vaccine effectiveness data from the literature...
September 2024: Lancet Respiratory Medicine
#55
MULTICENTER STUDY
Jin-Ji Yang, Jianying Zhou, Si-Yang Maggie Liu, Mingjun Li, Zhiye Zhang, Ying Cheng, Yun Fan, Hongming Pan, Baoqing Wang, Gongyan Chen, Ke Wang, Liyan Jiang, Yanping Hu, Jianhua Shi, Xiaorong Dong, Cuimin Ding, Yunpeng Liu, Zhe Liu, Wangjun Liao, Wei Li, Jun Wang, Shanyong Yi, Qiong Zhao, Aimin Zang, Yuan Chen, Jiuwei Cui, Pengfei Luo, Xionghu Shen, Meili Sun, Changli Wang, Yi-Long Wu
BACKGROUND: Currently approved targeted treatment for ROS1-rearranged non-small-cell lung cancer (NSCLC) has either inadequate intracranial activity or CNS-related toxicities. We evaluated the efficacy and safety of foritinib, a novel ALK and ROS1 inhibitor, in patients with advanced ROS1-rearranged NSCLC. METHODS: This two-part (phase 2a and 2b), multicentre, single-arm, open-label, phase 2 study was done in 29 centres in China. Eligible participants were adults (aged ≥18 years) with histologically or cytologically confirmed ROS1-rearranged, locally advanced or metastatic stage IIIB-IV NSCLC, with an Eastern Cooperative Oncology Group performance status of 2 or less...
September 2024: Lancet Respiratory Medicine
#56
JOURNAL ARTICLE
Bryant Furlow
No abstract text is available yet for this article.
September 2024: Lancet Respiratory Medicine
#57
RANDOMIZED CONTROLLED TRIAL
(no author information available yet)
BACKGROUND: Expanded criteria donors help to increase graft availability, but provide organs with an increased risk of delayed graft function. We aimed to investigate whether donor hypothermia decreases the risk of delayed graft function compared with normothermia. METHODS: We did this multicentre, randomised, controlled, parallel-arm trial at 53 intensive care units and transplant centres in France. We included expanded criteria donors in whom death was diagnosed based on neurological criteria, in compliance with French law, and the recipients of their kidney grafts...
September 2024: Lancet Respiratory Medicine
#58
(no author information available yet)
No abstract text is available yet for this article.
August 2024: Lancet Respiratory Medicine
#59
LETTER
Jérémie Pourchez, Clément Mercier, Lara Leclerc, Valérie Forest
No abstract text is available yet for this article.
August 2024: Lancet Respiratory Medicine
#60
LETTER
Srishti Chhabra, Yin Mo
No abstract text is available yet for this article.
August 2024: Lancet Respiratory Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
